Roxana Mehran, ESC 2021 – the PARADISE-MI Trial
Dr Roxana Mehran (Director of Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine, Mount Sinai Hospital, New York City, NY, USA) kindly shared her thoughts on the the PARADISE-MI trial (NCT02924727) from from the virtual ESC Congress 2021.
- What has been the impact of angiotensin receptor-neprilysin inhibitors (ARNIs) on the treatment of heart failure, and what unanswered questions remain? (0.13)
- What were the aims and design of the PARADISE-MI trial? (1.43)
- What were the secondary outcomes, and how well were they achieved? (3.23)
- What did you discover about coronary events after acute myocardial infarction? (5.14)
- What do you think will be the focus of research going forward? (8.50)
Speaker disclosures: Dr Roxana Mehran reports institutional research grants from Abbott, Abiomed, Applied Therapeutics, Arena, AstraZeneca, Bayer, Biosensors, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CellAegis, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Insel Gruppe AG, Medtronic, OrbusNeich, Philips; personal fees from ACC, Cine-Med Research, WebMD, SCAI; consulting fees paid to the institution from Abbott, Abiomed, AM-Pharma, Alleviant Medical, Bayer, Beth Israel Deaconess, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, DSI, Duke University, Idorsia Pharmaceuticals, Medtronic, Novartis, Philips; Equity <1% in Applied Therapeutics, Elixir Medical, STEL, CONTROLRAD (spouse); Scientific Advisory Board for AMA, Biosensors (spouse); Faculty CRF (no fee)..
Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.
Filmed during a remote video call with Dr Roxana Mehran as a highlight of ESC 2021, September 2021.
Share this Video
Related Videos In Heart Failure
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]
John Boehmer, ACC 2023: MicrocorTM device for heart failure management, the BMAD trial
The BMAD trial investigated patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, findings and clinical implications of the BMAD trial in […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!